ProMIS Neurosciences Inc.

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

PMN$3.98-1.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets


· · June 30, · · December 31, ·
· · 2026 · · 2025 ·
Assets
Current assets:
Cash	$53,429,280	$6,116,556
Short-term investments	33,753	33,753
Prepaid expenses and other current assets	3,230,900	3,032,112
Total current assets	56,693,933	9,182,421
Total assets	$56,693,933	$9,182,421
Liabilities and Shareholders' Equity
Current liabilities:
Accounts payable	$1,793,475	$2,543,415
Accrued liabilities	5,424,269	7,868,416
Total current liabilities	7,217,744	10,411,831
Share-based compensation liability	77,255	29,182
Total liabilities	7,294,999	10,441,013

Shareholders' equity (deficit):
Common Shares, no par value, unlimited shares authorized, 8,967,693 and 2,152,397 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	—	—
Additional paid-in capital	200,150,367	129,518,812
Accumulated other comprehensive loss	(371,184)	(371,184)
Accumulated deficit	(150,380,249)	(130,406,220)
Total shareholders' equity (deficit)	49,398,934	(1,258,592)
Total liabilities and shareholders' equity (deficit)	$56,693,933	$9,182,421

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.